BrightGene Bio-Medical Technology Co., Ltd. announced a private placement of A shares for gross proceeds of CNY 222,305,400 on June 7, 2022. The transaction will include participation from not more than 35 investors. The pricing base date of this non-public offering is the first day of the issue period, and the issue price is not less than 80% of the average price of the company's stocks 20 trading days before the first day of the issue period.

The number of non-public A shares issued this time does not exceed 30% of the company's total share capital before the issuance. The shares to be issued will have a hold period of 6 months. The transaction was approved by the board of directors of the company at its ninth meeting of the company's third directorate and is subject to approved by the Shanghai Stock Exchange and by China Securities Regulatory Commission.